Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C23H25N.ClH |
| Molecular Weight | 351.912 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(NCCC(C1=CC=CC=C1)C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=NJXWZWXCHBNOOG-UHFFFAOYSA-N
InChI=1S/C23H25N.ClH/c1-19(20-11-5-2-6-12-20)24-18-17-23(21-13-7-3-8-14-21)22-15-9-4-10-16-22;/h2-16,19,23-24H,17-18H2,1H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C23H25N |
| Molecular Weight | 315.4513 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Fendiline or Sensit (N-(3,3-diphenylpropyl)-(1-phenylethyl)-amine), is a diphenylalkylamine blocker of L-type calcium channels. Fendiline is an anti-anginal agent for the treatment of coronary heart disease. Pharmaco-dynamically, it exerts the typical calcium as well as calmodulin antagonistic actions: inhibition of the transmembrane calcium current, smooth muscle relaxation, negative inotropism, cardioprotection, inhibition of calmodulin-activated myosin light-chain kinase and phosphodiesterase. Pharmacokinetics reveal slow onset of action and a long half-life. The anti-anginal and anti-ischaemic efficacy of fendiline has been proven in several placebo-controlled, double-blind trials. Fendiline is an FDA-approved, albeit now clinically obsolete. Additionally, fendiline is a specific inhibitor of K-Ras plasma membrane localization that also inhibits K-Ras signal output and blocks the proliferation of K-Ras-transformed tumor cells.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/jm00335a011 | https://www.google.com/patents/US3262977
Curator's Comment: reference retrieved from www.drugfuture.com/chemdata/fendiline.html
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2095229 |
17.0 µM [IC50] | ||
Target ID: CHEMBL2189121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23129805 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Sensit Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.2 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.2 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.8 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
39.8 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
111.2 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
219.6 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/3566858/ |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
19.4 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
22 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
35.6 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/7117293/ |
75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENDILINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1200 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Trembling, Dizziness... AEs leading to discontinuation/dose reduction: Trembling Sources: Dizziness |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Dizziness | Disc. AE | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Trembling | Disc. AE | 400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no [Inhibition 20 uM] | ||||
| no [Inhibition 20 uM] | ||||
| no [Inhibition 20 uM] | ||||
Page: 1.0 |
yes [IC50 0.0871 uM] | |||
Page: 7.0 |
yes [IC50 13.8029 uM] | |||
Page: 6.0 |
yes [IC50 8.709 uM] | |||
| yes [Inhibition 80 uM] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| LuxR-dependent quorum sensing: computer aided discovery of new inhibitors structurally unrelated to N-acylhomoserine lactones. | 2010-08-01 |
|
| Contractile actions of L-type Ca2+ agonists in human vas deferens and effects of structurally different Ca2+ antagonists. | 2010-02-10 |
|
| Fendiline-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in human oral cancer cells. | 2009-01 |
|
| Interaction of antagonists with calmodulin: insights from molecular dynamics simulations. | 2008-06-12 |
|
| [Role of apoptosis in the kidney after reperfusion]. | 2008-02-17 |
|
| Allosteric modulators of GABA(B) receptors: mechanism of action and therapeutic perspective. | 2007-09 |
|
| Allosteric modulation of the calcium-sensing receptor. | 2007-09 |
|
| 2'-hydroxy-fendiline analogues as potent relaxers of isolated arteries. | 2007-04-30 |
|
| Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. | 2006-03 |
|
| Spectrofluorimetric determination of fendiline in tablets. | 2005-10 |
|
| GABA(B) receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area. | 2005-04 |
|
| 3-Chloro,4-methoxyfendiline is a potent GABA(B) receptor potentiator in rat neocortical slices. | 2005-01-10 |
|
| Allosteric modulation of GABA(B) receptor function in human frontal cortex. | 2005-01 |
|
| Clinical potential of GABAB receptor modulators. | 2005 |
|
| Calcimimetic and calcilytic drugs: just for parathyroid cells? | 2004-03 |
|
| Calcium sensing receptors as integrators of multiple metabolic signals. | 2004-03 |
|
| Arylalkylamines are a novel class of positive allosteric modulators at GABA(B) receptors in rat neocortex. | 2002-09-06 |
|
| The anti-anginal drug fendiline elevates cytosolic Ca(2+) in rabbit corneal epithelial cells. | 2002-07-19 |
|
| Fendiline mobilizes intracellular Ca2+ in Chang liver cells. | 2001-09 |
|
| Effects of the antianginal drug fendiline on Ca2+ movement in hepatoma cells. | 2001-07 |
|
| Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells. | 2001-07 |
|
| Determination of fendiline and gallopamil by capillary isotachophoresis. | 2001-06-15 |
|
| Dual effect of the antianginal drug fendiline on bladder female transitional carcinoma cells: mobilization of intracellular CA2+ and induction of cell death. | 2001-05 |
|
| Fendiline-Induced Ca2+ movement in A10 smooth muscle cells. | 2001-03-31 |
|
| The anti-anginal drug fendiline increases intracellular Ca(2+) levels in MG63 human osteosarcoma cells. | 2001-03-08 |
|
| Inhibitors of calmodulin impair the constitutive but not the inducible nitric oxide synthase activity in the rat aorta. | 1992-05 |
|
| Effects of the calmodulin antagonists fendiline and calmidazolium on aggregation, secretion of ATP, and internal calcium in washed human platelets. | 1991-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3566858
Pharmacokinetics in healthy volunteers: single doses of 200, 400, 600, 800, 1000, and 1200 mg; or 400 mg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2441812
Fendiline (100-200 microM) reduced the postsynaptic influx of calcium but did not alter calcium loss from the extracellular space into presynaptic terminals in the rat hippocampus in vitro.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:45:47 GMT 2025
by
admin
on
Mon Mar 31 18:45:47 GMT 2025
|
| Record UNII |
HEM3Z10IIK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000092346
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
13636-18-5
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
m5272
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | Merck Index | ||
|
26154
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
SUB02113MIG
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
757826
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
237-121-5
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
DTXSID2045860
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | |||
|
236767
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY | RxNorm | ||
|
HEM3Z10IIK
Created by
admin on Mon Mar 31 18:45:47 GMT 2025 , Edited by admin on Mon Mar 31 18:45:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |